Dongwha Pharm.Co.,Ltd Statistics
Total Valuation
Dongwha Pharm.Co.,Ltd has a market cap or net worth of KRW 186.26 billion. The enterprise value is 252.70 billion.
Market Cap | 186.26B |
Enterprise Value | 252.70B |
Important Dates
The last earnings date was Thursday, November 14, 2024.
Earnings Date | Nov 14, 2024 |
Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Dongwha Pharm.Co.,Ltd has 27.72 million shares outstanding. The number of shares has increased by 0.09% in one year.
Current Share Class | n/a |
Shares Outstanding | 27.72M |
Shares Change (YoY) | +0.09% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 13.42% |
Owned by Institutions (%) | 9.25% |
Float | 18.43M |
Valuation Ratios
The trailing PE ratio is 13.39.
PE Ratio | 13.39 |
Forward PE | n/a |
PS Ratio | 0.46 |
PB Ratio | 0.50 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.94, with an EV/FCF ratio of -17.63.
EV / Earnings | 18.18 |
EV / Sales | 0.62 |
EV / EBITDA | 8.94 |
EV / EBIT | 20.54 |
EV / FCF | -17.63 |
Financial Position
The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.10.
Current Ratio | 2.38 |
Quick Ratio | 1.56 |
Debt / Equity | 0.10 |
Debt / EBITDA | 1.39 |
Debt / FCF | -2.72 |
Interest Coverage | 11.70 |
Financial Efficiency
Return on equity (ROE) is 3.42% and return on invested capital (ROIC) is 1.79%.
Return on Equity (ROE) | 3.42% |
Return on Assets (ROA) | 1.46% |
Return on Capital (ROIC) | 1.79% |
Revenue Per Employee | 511.66M |
Profits Per Employee | 17.53M |
Employee Count | 793 |
Asset Turnover | 0.78 |
Inventory Turnover | 3.20 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.21% in the last 52 weeks. The beta is 1.06, so Dongwha Pharm.Co.,Ltd's price volatility has been similar to the market average.
Beta (5Y) | 1.06 |
52-Week Price Change | -30.21% |
50-Day Moving Average | 7,597.40 |
200-Day Moving Average | 8,464.15 |
Relative Strength Index (RSI) | 23.53 |
Average Volume (20 Days) | 67,933 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Dongwha Pharm.Co.,Ltd had revenue of KRW 405.75 billion and earned 13.90 billion in profits. Earnings per share was 501.80.
Revenue | 405.75B |
Gross Profit | 200.51B |
Operating Income | 12.17B |
Pretax Income | 19.52B |
Net Income | 13.90B |
EBITDA | 28.12B |
EBIT | 12.17B |
Earnings Per Share (EPS) | 501.80 |
Balance Sheet
The company has 62.06 billion in cash and 39.05 billion in debt, giving a net cash position of 23.01 billion or 830.23 per share.
Cash & Cash Equivalents | 62.06B |
Total Debt | 39.05B |
Net Cash | 23.01B |
Net Cash Per Share | 830.23 |
Equity (Book Value) | 410.21B |
Book Value Per Share | 13,492.75 |
Working Capital | 131.22B |
Cash Flow
In the last 12 months, operating cash flow was 12.91 billion and capital expenditures -27.25 billion, giving a free cash flow of -14.34 billion.
Operating Cash Flow | 12.91B |
Capital Expenditures | -27.25B |
Free Cash Flow | -14.34B |
FCF Per Share | -517.27 |
Margins
Gross margin is 49.42%, with operating and profit margins of 3.00% and 3.43%.
Gross Margin | 49.42% |
Operating Margin | 3.00% |
Pretax Margin | 4.81% |
Profit Margin | 3.43% |
EBITDA Margin | 6.93% |
EBIT Margin | 3.00% |
FCF Margin | -3.53% |
Dividends & Yields
This stock pays an annual dividend of 180.00, which amounts to a dividend yield of 2.71%.
Dividend Per Share | 180.00 |
Dividend Yield | 2.71% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 35.89% |
Buyback Yield | -0.09% |
Shareholder Yield | 2.62% |
Earnings Yield | 7.47% |
FCF Yield | -7.70% |
Stock Splits
The last stock split was on June 30, 2009. It was a forward split with a ratio of 5.
Last Split Date | Jun 30, 2009 |
Split Type | Forward |
Split Ratio | 5 |
Scores
Dongwha Pharm.Co.,Ltd has an Altman Z-Score of 2.88. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.88 |
Piotroski F-Score | n/a |